A new study published in the NEJM Evidence journal showed that automated insulin delivery reduced hypoglycemia in older ...

Bernstein analyst Lee Hambright raised the firm’s price target on Tandem Diabetes (TNDM) to $44 from $42 and keeps an Outperform rating on the ...

The Irvine, California-based company makes an insulin pump called the iLet Bionic Pancreas, which was cleared by the Food and ...

Glooko’s integration of Hedia’s diabetes tech aims to improve care for patients and enhance healthcare provider insights.

In a report released today, Lee Hambright from Bernstein maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report), with a price ...

The convergence of advanced technologies and advancements in drug delivery is reshaping diabetes care. Digital therapeutics ...

This research and delivery system will help patients with type 1 and type 2 diabetes receive their insulin based on real-time glucose levels.

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) on January 6 and set a price ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it signed a multi-year R&D collaboration agreement with the ...